It is used solely as a research tool for exploring peptide-driven signalling mechanisms in vitro, and no conclusions about biological effects in humans or animals should be drawn from this work
Elevated IGF-1 drives many of GH effects, both beneficial and problematic

General Guidelines Commit to a full cycle most skin and hair peptides take 812 weeks to show visible results Consistency matters daily or scheduled dosing is key to driving collagen synthesis and hair follicle activity Combine systemically and topically stacking injectable or systemic peptides with GHK-Cu topical gives superior results Support with nutrition adequate protein , vitamin C , copper , and zinc are essential to fuel collagen and elastin production Dosing and Timing Practical Application If focused on skin anti-aging and glow : GHK-Cu (topical + injectable if desired) CJC-1295 + Ipamorelin BPC-157 (if recovering from laser or microneedling) If focused on hair density and growth : GHK-Cu (scalp topical + injectable) BPC-157 + TB500 (systemic support for scalp blood flow and follicle health) CJC-1295 + Ipamorelin (optional GH optimization) If recovering from surgery, scars, or skin injury : BPC-157 daily TB500 for enhanced tissue remodeling GHK-Cu topically + injectable if needed Realistic Expectations 812 weeks visible skin improvements (elasticity, tone, hydration, glow) 12+ weeks hair density improvements begin to show (varies by cause of hair loss) Ongoing use supports maintenance and further progression Peptide-based interventions require sustained application to produce visible dermal and hair regeneration outcomes, with the most significant effects observed after 23 months of consistent use. Ginsburg et al., Dermatologic Therapy Stacking Peptides for Enhanced Skin and Hair Results While individual peptides can deliver impressive skin and hair benefits on their own, synergistic stacking produces the most powerful and comprehensive results

Other amylin-based molecules which are in early stage clinical trials include long-acting amylin agonists and a dual amylin and calcitonin RA (Table 1)
Note that fixed costs are known in total, but Amy does not allocate fixed costs to each department